A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

Study Identifier:
365-201-00001
ClinicalTrials.gov Identifier:
NCT07649265
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
844-687-3522 or [email protected]
Will Be Recruiting
Subscribe to Updates

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: HBM7020
Date
Sep 2026 - Nov 2028
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Key Inclusion Criteria for Healthy Participants (Part 1)
  • Participants who are of non-childbearing potential or are using acceptable contraception.
  • Body mass index (BMI) and body weight within an acceptable range.
  • Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.
  • Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 1)
  • BMI and body weight within an acceptable range.
  • Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.
  • Key Disease-Specific Inclusion Criteria for Patient Participants (Part 1)
  • Confirmed autoimmune disease with appropriate supporting autoantibody findings.
  • Stable background therapy prior to dosing.
  • Active moderate to severe disease consistent with protocol-defined disease activity criteria for:
  • Systemic lupus erythematosus (SLE)
  • Systemic sclerosis (SSc)
  • Rheumatoid arthritis (RA)
  • Sjögren's disease (SjD)
  • Key Inclusion Criteria for Rescreening Participants (Part 2)
  • Meets Part 1 disease-agnostic inclusion criteria.
  • Stable background autoimmune therapy prior to dosing.
  • Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.
  • Key Exclusion Criteria for Parts 1 and 2
  • Pregnant or breastfeeding participants.
  • Recent vaccination within protocol-defined timelines.
  • Clinically significant medical history or abnormal physical examination findings.
  • Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
  • Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
  • Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.

Protocol Summary

This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).

Study Locations

No locations found.
© 2025 Otsuka America Pharmaceutical, Inc.
All rights reserved.

July 2025 01US25EUC0279

Requirements information
Inclusion criteria
  • Key Inclusion Criteria for Healthy Participants (Part 1)
  • Participants who are of non-childbearing potential or are using acceptable contraception.
  • Body mass index (BMI) and body weight within an acceptable range.
  • Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.
  • Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 1)
  • BMI and body weight within an acceptable range.
  • Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.
  • Key Disease-Specific Inclusion Criteria for Patient Participants (Part 1)
  • Confirmed autoimmune disease with appropriate supporting autoantibody findings.
  • Stable background therapy prior to dosing.
  • Active moderate to severe disease consistent with protocol-defined disease activity criteria for:
  • Systemic lupus erythematosus (SLE)
  • Systemic sclerosis (SSc)
  • Rheumatoid arthritis (RA)
  • Sjögren's disease (SjD)
  • Key Inclusion Criteria for Rescreening Participants (Part 2)
  • Meets Part 1 disease-agnostic inclusion criteria.
  • Stable background autoimmune therapy prior to dosing.
  • Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.
  • Key Exclusion Criteria for Parts 1 and 2
  • Pregnant or breastfeeding participants.
  • Recent vaccination within protocol-defined timelines.
  • Clinically significant medical history or abnormal physical examination findings.
  • Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
  • Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
  • Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.

We defy limitation,

so that others can too.

Follow Us
OAPI and OPDC Locations

508 Carnegie Center Dr,

Princeton, NJ 08540, United States

Phone 609-524-6788

2440 Research Blvd,

Rockville, MD 20850, United States

Phone 301-424-9055

3956 Point Eden Way

Hayward, CA 94545, United States

Phone 800-562-3974